Co-treatment with cisplatin in mice carrying xenografts formed from knockdown of AKT2 (4T1 shAKT2) and AKT3 (4T1 shAKT3) in 4T1 cells dramatically attenuated tumor formation in mice after two weeks as compared with that of mice with knockdown of AKT1 (4T1 shAKT1) treated with cisplatin (Figure 8A). This evidence concerns the gene AKT1 and neoplasm.